A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of BIND-014 in patients with advanced non-small cell lung cancer (NSCLC).
Non-small Cell Lung Cancer
DRUG: BIND-014
Number of patients with either a complete or partial response, To determine the efficacy of BIND-014 as measured by objective response rate (ORR) in patients with Stage III/IV Non-small cell lung cancer (NSCLC) who have failed one prior platinum containing chemotherapy regimen for advanced or metastatic disease., Patients will be followed for the duration of treatment, an expected average of 18 weeks
Number of patients who experience adverse events, To assess the safety and tolerability of BIND-014, Patients will be followed for the duration of treatment, an expected average of 18 weeks
The purpose of this study is to evaluate the efficacy and safety of BIND-014 in patients with advanced non-small cell lung cancer (NSCLC).